Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Arnon Nagler, MD, MSc, Chaim Sheba Medical Center, Tel-Hashomer, Israel, discusses the results of the survey evaluating minimal residual disease (MRD) testing for acute lymphoblastic leukemia (ALL) in European Blood and Marrow Transplantation (EBMT) transplant centers. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).